One of the largest biotech investment conferences is just around the corner. Now in its 19th year, BIO 2017 CEO & Investor Conference will be held at the Waldorf Astoria in New York Feb 13-14. More than 175 company presentations, issue-oriented plenary and educational sessions, networking opportunities and one-on-one partnering are all scheduled for the two day event which brings together senior biotech analysts, members of congress and top industry investors. It is an ideal venue to hear first-hand from leading biotech executives, investors and policymakers who will drive the future of the industry.
High profile thought leaders will be interviewed during six Fireside Chats interspersed throughout the program of therapeutic workshops and business educational panels. These influential innovators include:
- Giovanni Caforio – CEO, Bristol-Myers Squibb
- Tony Coles – Chairman and CEO, Ymanity
- Kathy High – Co-Founder, President and Chief Medical Officer, Spark Therateutics
- J. Joseph Kim – President and CEO Inovio Pharmaceuticals
- Lynn Seely, CEO, Myovant Sciences
The entire program can be viewed here. Highlights include:
New discoveries are finding links that extend significantly beyond the gut microbiome and intestinal disorders into a range of bodily systems including the immune and nervous systems. Major biopharma companies have engaged in significant deals that envision treatments to commercialize from this research and leading companies are pushing forward on clinical trials. This session will outline the microbiome influenced therapies most likely to create major effects for patients.
- Pierre Belichard, PharmD, PhD, Chief Executive Officer, Enterome
- Nick Conley, PhD, Board of Directors, Co-founder & Chief Executive Officer, EpiBiome
The scourge of rising addiction and heroin overdoses has been associated with the growth in usage of important, opioid-based, prescription pain treatments. New approaches to pain control are looking at different biological mechanisms and methodologies for improving patients’ lives with lower risks of ill effects or addiction. This session will speak with experts developing therapeutic innovations that do not rely on opioid-based drugs and can provide doctors additional alternatives for helping patients.
- Russell Herndon, President and Chief Executive Officer, Hydra Biosciences
- Jeffrey B. Kindler, Chief Executive Officer, Centrexion Therapeutics
- Gail Cawkwell, MD, Chief Medical Officer, Purdue Pharma
As biotech IPO activity has cooled from its 2015 peak, companies are more deliberately weighing reverse mergers and other alternatives to benefiting from the capital in public markets. With post-election market uncertainty, does the IPO market for 2017 seek to rise, fall, or stay level? What markers should CEOs watch for to gauge their timing and choices? This session will feature experienced voices for explaining the practical techniques for getting into public markets and what investors are expecting to see in order to win their support.
- John Chambers, President and Head of Investment Banking, H.C. Wainwright & Co., LLC
- Brian Hagerty, Senior Director, Head of Healthcare Capital Markets, New York Stock Exchange
- Douglas E. Onsi, Chief Financial Officer, Leap Therapeutics, Inc.
- Sapna Srivastava, former Chief Financial Officer and Chief Strategy Officer, Intellia Therapeutics
From a healthcare policy point of view, 2017 has the potential of being the most dramatic since the initial introduction of the Affordable Care Act. The new Trump Administration has suggested an interest in making wholesale changes in how medicines are regulated and paid for by the U.S. government. PDUFA will expire later this year if its planned replacement is not passed in a timely fashion, greatly complicating companies’ drug development strategies and budgets. This session will share the latest details on what policies the Trump Administration and Congress are pursuing that would support or upend the assumptions that biopharma executives and investors have built into their financial models.
- Elizabeth Krutoholow, Senior Analyst, Bloomberg Intelligence
- Richard Pops, Chairman and Chief Executive Officer, Alkermes
The passage by Congress of the 21st Century Cures Act in late 2016 has opened up new opportunities and expectations for the design of clinical trials that the FDA will consider for regulatory review. Real world evidence and the stronger inclusion of patient perspectives on endpoints are two examples of the shifts that will impact therapy development. This session will explain the advantages and complications that drug developers and investors should be aware of as the Cures Act gets implemented.
- Gregory W. Daniel, PhD, MPH, RPh, Deputy Director, Duke-Margolis Center for Health Policy
- Susan Peschin, MHS, President and Chief Executive Officer, Alliance for Aging Research
Also offered is BIO One-on-One Partnering™, a resource for scheduling private meetings in advance of the conference. Over 2,500 meetings are expected to be scheduled during the two day event!
Register here to take advantage of this opportunity to connect with the biotech investment community.
Complimentary media registration is provided to qualified members of the press.